Clinical Cardiology and Heart Failure
Enrollment in this trial is temporarily on hold.
This clinical trial is for men and women who are diagnosed with ischemic or congestive heart failure (CHF) after a myocardial infarction (MI or “heart attack”).
The purpose of the study is to assess the efficacy and long-term safety of the CardioKinetix Parachute device, an umbrella-shaped membrane that is is implanted inside the left ventricle of the heart. This creates a partition in the ventricle, reducing the effective size of the chamber and restoring its natural shape somewhat, which has been shown to be important for the treatment of heart failure. It is implanted with a catheter procedure, avoiding the risks of surgery.
Study subjects will be followed up for 5 years after placement of the stent.
Enrollment in this study is temporarily on hold.
This clinical trial is for men and women moderate to severe heart failure (HF). The purpose of the study is to assess the safety and efficacy of the C-Pulse System, a device that is intended to relieve heart failure symptoms, improve quality of life and cardiac function, and reduce the need for heart failure hospitalization.
Unlike traditional heart assist devices, the C-Pulse system includes a small cuff around the aorta that inflates and deflates as the heart beats, increasing the heart’s oxygen supply and reducing the stress on the pumping chamber. It is implanted outside the bloodstream, and maybe disconnected for personal hygiene.
Study subjects are follow up for five years after the device is implanted.
This clinical trial is for men and women who are being treated for with Pulmonary Hypertension (PH) or pulmonary arterial hypertension (PAH) but continue to experience symptoms such as shortness of breath during exertion, dizziness, or fainting spells.
The purpose of this study is to evaluate the use of inhaled nitric oxide (iNO) with a pulsed delivery device (INOpulse DS). Similar treatments are approved only for conditions found in newborn babies.
There are two parts to this study. For the first 16 weeks, subjects are randomized to receive either one of two doses of iNO delivered by a pulsed delivery device, or a placebo. All subjects who complete this part of the study are eligible to enter an extended study in which all subjects receive iNO. This part of the study continues until the entire study is closed.